Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in incurable stage IIIB/IV non-small cell lung cancer
NCT00036647Phase 3Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Nov 2001
- Primary completion
- Jan 2004
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by OSI Pharmaceuticals. Primary endpoint: Overall Survival. Started Nov 2001; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00036647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036647.